Genomic Cancer Testing Market, By Test Type (Genomic Profiling Tests, Liquid Biopsy Tests, Companion Diagnostic Tests, Pharmacogenomic Tests, Hereditary Cancer Tests, Other specialized genomic tests), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Melanoma, Leukemia, Lymphoma, Other specific cancer types), By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence In Situ Hybridization, Microarray, Immunohistochemistry, Other genomic testing technologies), By End-User (Hospitals, Diagnostic Laboratories, Academic and Research Institutions, Cancer Centers, Other healthcare providers), By Biomarker Type (Genetic Biomarkers, Protein Biomarkers, Molecular Biomarkers, Epigenetic Biomarkers), By Service Provider (Diagnostic Laboratories, Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations), By Application (Targeted Therapy Selection, Disease Monitoring, Prognostic Testing, Companion Diagnostics, Risk Assessment, Pharmacogenomic Testing), By Testing Setting (In-House Testing, Outsourced Testing), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Select a license type that suits your business needs
Single User License
US$ 4,500
US$ 3,500
Three thousand five hundred dollars
Frequently purchased
Multi User License
US$ 7,000
US$ 5,500
Five thousand five hundred dollars
Corporate User License
US$ 10,000
US$ 7,500
Seven thousand five hundred dollars
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients